jurnalul român de psihofarmacologie romanian journal of ...

192. Hale AS. A review of the safety and tolerability of sertindole. Int Clin Psychopharmacol
1998; 13(Suppl. 3):65-70.
193. Wright P, Birkett M, David SR, Meehan K, Ferchland I, Alaka NJ, Saunders JC, Krueger J,
Bradley P, San L, Bernardo M, Reinstein M, Breier A. A double-blind, placebo controlled
comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of
acute agitation in schizophrenia. Am J Psychiatry 2001; 158:1149-1151.
194. Meehan K, Zhang F, David S, Tohen M, Janicak P, Small J, Koch M, Rizk R, Walker D,
Tran P, Beier A. A double-blind, randomized comparison of the efficacy and safety of
intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated
patients diagnosed with bipolar mania. J Clin Psychopharmacol 2001; 21:389-397.
195. Keck P Jr, Buffenstein A, Ferguson J, Feighner J, Jaffe W, Harrigan EP, Morrissey MR.
Ziprasidone Study Group. Ziprasidone 40 and 20 mg/day in the acute exacerbation of
schizophrenia and schizoaffective disorder: a 4-week placebo controlled trial.
Psychopharmacology 1998; 140:173-184.
196. Goff DC, Posever T, Herz L, Simmons J, Kletti N, Lapierre K, Wilner KD, Law CG, Ko
GN. An exploratory haloperidol-controlled dose-finding study of ziprasidone in
hospitalized patients with schizophrenia or schizoaffective disorder. J Clin
Psychopharmacol 1998; 18:296-304.
197. Brook S, Lucey JV, Gunn KP. Intramuscular ziprasidone compared with intramuscular
haloperidol in the treatment of acute psychosis. Ziprasidone IM Study Group. J Clin
Psychiatry 2000; 61:933-941.
198. Daniel DG, Potkin SG, Reeves KR, Swift RH, Harrigan EP. Intramuscular (IM) ziprasidone
20 mg is effective in reducing acute agitation associated with psychosis: a double-blind,
randomized trial. Psychopharmacology 2001; 155:128-134.
199. Lesem MD, Zajecka JM, Swift RH, Reeves KR, Harrigan EP. Intramuscular ziprasidone, 2
mg versus 10 mg, in the short-term management of agitated psychotic patients. J Clin
Psychiatry 2001; 62:12-18.
200. Sallee FR, Kurlan R, Goetz CG, Singer H, Scahill L, Law G, Dittman VM, Chappell PB.
Ziprasidone treatment of children and adolescents with Tourette’s syndrome: a pilot study.
J Am Acad Child Adolesc Psychiatry 2000; 39:292-299.
201. Gunn KP, Harrigan EP, Heym J. The safety and tolerability of ziprasidone treatment. In:
Critical Issues in the treatment of schizophrenia. Brunello N, Racagni G, Langer SZ,
Mendlewicz J (eds.) Kerger, Basel 1995; 10:172-177.
202. Miceli JJ. Cardiovascular safety profile of ziprasidone (Abstract). World J Biol Psychiatry
2001; 2:384.
148